| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 10/10/2001 | EP1140784A2 Ion channel modulating agents |
| 10/10/2001 | EP1140783A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| 10/10/2001 | EP1140768A1 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases |
| 10/10/2001 | EP1140291A1 Combination chemotherapy comprising a mitotic inhibitor and a mek inhibitor |
| 10/10/2001 | EP1140289A1 Method for prevention and treatment of cancer and other cell proliferative diseases with ultrasonic energy |
| 10/10/2001 | EP1140273A2 Device for locally delivering a drug in a body cavity |
| 10/10/2001 | EP1140194A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia |
| 10/10/2001 | EP1140193A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 10/10/2001 | EP1140192A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia |
| 10/10/2001 | EP1140189A1 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| 10/10/2001 | EP1140186A1 Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
| 10/10/2001 | EP1140183A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 10/10/2001 | EP1140182A2 Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia |
| 10/10/2001 | EP1140181A1 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia |
| 10/10/2001 | EP1140179A2 Use of a cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 10/10/2001 | EP1140178A2 Use of a matrix metallaproteinase inhibitor and radiation as a combined treatment of neoplasia |
| 10/10/2001 | EP1140177A2 Use of an integrin antagonist and radiation in the treatment of neoplasia |
| 10/10/2001 | EP1140175A2 Antibodies to truncated vegf-d and uses thereof |
| 10/10/2001 | EP1140173A2 Vascular endothelial cell growth factor antagonists and uses thereof |
| 10/10/2001 | EP1140171A1 Methods and products for regulating lectin complement pathway associated complement activation |
| 10/10/2001 | EP1140169A2 Methods and compositions for decreasing allergic reactions to surface allergens |
| 10/10/2001 | EP1140150A2 Method for accelerating the rate of mucociliary clearance by using a kunitz-type serine protease inhibitor |
| 10/10/2001 | EP1140142A2 Treatment of hepatitis c virus infections with interleukin-10 |
| 10/10/2001 | EP1140141A2 Methods for treating cancer and for mediating chemotaxis of dendritic cells |
| 10/10/2001 | EP1140132A1 Gonadotropin releasing hormone antagonist |
| 10/10/2001 | EP1140130A2 Inhibition of angiogenesis by high molecular weight kininogen domain 3 peptide analogs |
| 10/10/2001 | EP1140125A1 Extracts of celery seed for the prevention and treatment of pain, inflammation and gastrointestinal irritation |
| 10/10/2001 | EP1140119A1 Novel therapeutic application of low molecular weight heparin |
| 10/10/2001 | EP1140118A1 Cyclic adenosine diphosphate ribose analogues for modulating t cell activity |
| 10/10/2001 | EP1140108A1 Method and composition for treatment of female sexual dysfunction |
| 10/10/2001 | EP1140105A1 Controlled release galantamine composition |
| 10/10/2001 | EP1140098A2 Tricyclic nitrogen heterocycles as pde iv inhibitors |
| 10/10/2001 | EP1140085A1 Azabicycloalkanes as ccr5 modulators |
| 10/10/2001 | EP1140078A2 Benzimidazole vascular damaging agents |
| 10/10/2001 | EP1140076A1 Use of 5ht3-receptor antagonists for the treatment of chronic fatigue syndrome |
| 10/10/2001 | EP1140074A1 Indole and indolizidine derivatives for the treatment of migraine |
| 10/10/2001 | EP1140073A1 Combinations of farnesyl transferase inhibitors and irinotecan or camptothecin for treating cancer |
| 10/10/2001 | EP1140067A1 Antiviral method using mek inhibitors |
| 10/10/2001 | EP1140065A1 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease |
| 10/10/2001 | EP1140063A1 Method and composition for the maintenance and restitution of gut integrity |
| 10/10/2001 | EP1140056A2 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life |
| 10/10/2001 | EP1140055A1 Use of a 5ht 2a? and 5ht 2a/c? receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways |
| 10/10/2001 | EP1140049A2 Compositions and methods to inactivate n-type calcium channels |
| 10/10/2001 | EP1140048A2 Methods for treating certain diseases using naaladase inhibitors |
| 10/10/2001 | EP1140047A2 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs |
| 10/10/2001 | EP1140046A1 Use of a mek inhibitor for preventing transplant rejection |
| 10/10/2001 | EP1140044A2 cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION |
| 10/10/2001 | EP1140026A1 Biodegradble polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| 10/10/2001 | EP1140025A1 Granules for oral administration, process for producing the same, and tablets produced from the granules |
| 10/10/2001 | EP1140024A2 Particles for oral delivery of peptides and proteins |
| 10/10/2001 | EP1139996A1 Deodorizing cosmetic agents |
| 10/10/2001 | EP1139974A1 Soy depigmenting and skin care compositions |
| 10/10/2001 | EP1139913A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 10/10/2001 | EP1139793A2 Inhibitors of the bitter taste response |
| 10/10/2001 | EP1139753A1 Formulations for treating disease and methods of using same |
| 10/10/2001 | EP1139752A1 Methods and compositions for treatment of cell proliferative disorders |
| 10/10/2001 | EP1139750A1 Bone sialoprotein based toxic gene therapy for the treatment of calcified tumors and tissues |
| 10/10/2001 | EP0956036A4 Anti-fibrotic agent assay |
| 10/10/2001 | EP0923566A4 High molecular weight polymer-based prodrugs |
| 10/10/2001 | EP0840731B1 Polycyclic alcaloid-derivatives as nmda-receptor antagonists |
| 10/10/2001 | EP0840620B1 Il-8 antagonists for treatment of asthma |
| 10/10/2001 | EP0793476B1 Use of Mangiferin or Derivatives thereof for Cosmetic Applications |
| 10/10/2001 | EP0765320B1 Benzimidazolone derivatives with central dopaminergic activity |
| 10/10/2001 | CN1317047A GBS toxin receptor |
| 10/10/2001 | CN1317045A Pharmaceutical uses of NAB1 and NAB2 |
| 10/10/2001 | CN1317005A Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
| 10/10/2001 | CN1316995A Hydroxy 2-pipecolate hydroxamide acid derivatives as MMP inhititors |
| 10/10/2001 | CN1316906A Stable liquid formulations of botulinum toxin |
| 10/10/2001 | CN1316902A Therapeutic compositions (II) |
| 10/10/2001 | CN1316432A Cell death inhibitory albumen |
| 10/10/2001 | CN1316419A Arenesulfonyl amino-iso hydroximic acid derivative |
| 10/10/2001 | CN1072669C Benzimidazole compounds and their use as modulators of the GABAA receptor complex |
| 10/10/2001 | CN1072667C Mercaptoalkylpeptidyl compounds having imidzole substituent and their use as inhibitors of matrix metalluproteinass (MMP) and/or tumour necrosis factor (TNF) |
| 10/10/2001 | CN1072666C (Azetidin-1-ylalkyl) lactams as tachykinin antagonists |
| 10/10/2001 | CN1072664C Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compound |
| 10/10/2001 | CN1072647C Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors |
| 10/10/2001 | CN1072491C Nutritive liquid for nourishing brain and promoting intelligence growth |
| 10/10/2001 | CN1072488C Hair and beard blackening liquor |
| 10/10/2001 | CN1072483C Stable, ingestabl and absorbadle NADH and NADPH therapeutic compositions |
| 10/10/2001 | CN1072481C Wrinkle eliminating cream and its preparation method |
| 10/10/2001 | CA2343426A1 Compound, specificially for cosmetic use, containing a steroid and a 2-alkyl acanol or an ester |
| 10/09/2001 | WO2000066625A1 Soybean protein nutraceuticals |
| 10/09/2001 | US6300499 α1-adrenergic receptor antagonists |
| 10/09/2001 | US6300476 Anti-peptide antibody against human cytochrome P450 3A4 |
| 10/09/2001 | US6300472 Rab proteins |
| 10/09/2001 | US6300373 Antiproliferative and neurotrophic molecules |
| 10/09/2001 | US6300372 3-Cyano-3-(3,4-disubstituted) phenylcyclohexyl-1-carboxylates |
| 10/09/2001 | US6300365 Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
| 10/09/2001 | US6300363 Indole compounds as COX-2 inhibitors |
| 10/09/2001 | US6300359 (E)-3-[1-n-Butyl-5-[2-(2-carboxyphenyl)methoxy-4-chlorophenyl]-1H-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-enoic acid monoargininyl salt |
| 10/09/2001 | US6300358 Administering benzydamine or a physiologically acceptable acid addition salt for therapy of condition caused by tumor necrosis factor |
| 10/09/2001 | US6300356 Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist |
| 10/09/2001 | US6300352 For therapy of asthma |
| 10/09/2001 | US6300351 For inhibiting human immunodeficiency virus-1 (hiv-1) reverse transcriptase |
| 10/09/2001 | US6300350 Administering to mammal an retinoic acid (rar) agonist that is at least gamma selective and is rar.alpha. sparing for treating emphysema |
| 10/09/2001 | US6300347 For therapy of tumor necrosis factor and interleukin-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis |
| 10/09/2001 | US6300344 Heterocyclic compounds |
| 10/09/2001 | US6300342 Antithrombotic phenylalkyl derivatives |
| 10/09/2001 | US6300335 Urogenital disorders |
| 10/09/2001 | US6300334 Thieno[2,3-d]pyrimidine-2,4-diones |